Brain Tumor Panel

Test Information

This is a comprehensive panel testing for gains, losses and LOH in brain tumor specimens along with IDH1 targeted mutation analyses.

Turnaround Time

10 days

CPT Code(s)

81406

Cost

$1,000

Genes

Disorders

Clinical Information

Brain Tumors represent only a small fraction of the overall cancer diagnoses in the U.S. with 1.4% of new cases classified as brain or other nervous system cancers. National Cancer Institute (NCI) estimates 23,800 people to be diagnosed with brain cancer in 2017 and 16,700 people are projected to die (https://seer.cancer.gov/statfacts/html/brain.html). Additionally, the 5-year survival for these patients is reported to be 33.6%. Glioblastoma (GBM) is the most common malignant brain tumor in adults and is characterized by aggressive phenotype and poor prognosis. For GBM, 5-year survival rates are only 3-5%. One of the difficulties in treating GBM, and gliomas in general, is the amount of inter- and intra-tumoral heterogeneity present in these malignancies. However, advancements in molecular and sequencing technology have resulted in the molecular characterization of many recurrent genetic abnormalities in gliomas and hence affecting therapeutic management.

Indications

Gene sequencing and targeted mutation testing and copy number analysis can serve as a useful diagnostic and potentially prognostic tool for the analysis of affected tissues or tumors. The detection of copy number variants or specific gene mutations may enhance treatment decisions.

Specimen Requirements

Analysis can be performed on fresh or frozen tissue samples as well as formalin-fixed, paraffin-embedded tissue samples.

Transport Instructions

The specimen should be kept at the appropriate temperature and delivered via overnight shipping.

Have Questions Need Support?

Call our laboratory at 1-800-473-9411 or contact one of our Laboratory Genetic Counselors for assistance.
Robin Fletcher, MS, CGC
Kellie Walden, MS, CGC

Oncology Testing, Panel
Meet Makayla Gunn

Meet Makayla Gunn

Makayla was diagnosed with Rett Syndrome in April of 2015 at the age of two.   At about 18 months, we noticed she had started some repetitive hand motions, and her pediatrician was a little concerned that she did not have many words.  She had learned some sign language, and was saying ‘mama’ and ‘dada’, but that was it.  Then she suddenly stopped all of that.  At her 2 year old check-up, the pediatrician referred us to BabyNet, ...

In The News